Charles Schwab
HEPA

Charles Schwab’s Hepion Pharmaceuticals HEPA Stock Holding History

Charles Schwab’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-32
Closed -$24.5K – 3637
2023
Q1 		$24.5K Hold
32
– – ﹤0.01% 3483
2022
Q4 		$9.46K Hold
32
– – ﹤0.01% 3534
2022
Q3 		$16K Hold
32
– – ﹤0.01% 3492
2022
Q2 		$19K Hold
32
– – ﹤0.01% 3522
2022
Q1 		$41K Hold
32
– – ﹤0.01% 3551
2021
Q4 		$36K Hold
32
– – ﹤0.01% 3536
2021
Q3 		$49K Hold
32
– – ﹤0.01% 3454
2021
Q2 		$63K Hold
32
– – ﹤0.01% 3335
2021
Q1 		$59K Buy
+32
New +$70.2K ﹤0.01% 3423

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Charles Schwab's HEPA Position: Q2 2023 in Review

Charles Schwab sold out of Hepion Pharmaceuticals (HEPA) in Q2 2023, closing a stake of 32 shares — an estimated $24.5K sold.

Charles Schwab first reported a position in HEPA in Q1 2021 and held it in 9 quarters. The position peaked at $63K in Q2 2021. 16 funds tracked by Wall St. Rank hold HEPA as of Q2 2023.

  • Charles Schwab reported no remaining Hepion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Charles Schwab sold 32 Hepion Pharmaceuticals shares in Q2 2023, an estimated $24.5K.
  • Charles Schwab first reported a position in Hepion Pharmaceuticals in Q1 2021 and held it in 9 quarters.
  • Charles Schwab's Hepion Pharmaceuticals position peaked at $63K in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2023.

Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.